Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 21, Issue 9, 1998, Pages 602-611

  Hall, J E ^a   Taylor, A E ^a   Hayes, F J ^a   Crowley Jr , W F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Androgens; Follicle stimulating hormone; Gonadotropin releasing hormone; Luteinizing hormone; Reproduction

Indexed keywords

ACTIVIN; ANDROGEN; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADOTROPIN; INHIBIN; LUTEINIZING HORMONE; PROGESTERONE;

ADENOHYPOPHYSIS; ARTICLE; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NEGATIVE FEEDBACK; NEUROENDOCRINOLOGY; OBESITY; OVARY POLYCYSTIC DISEASE; PULSATILE HORMONE RELEASE;

EID: 0031720852     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350785     Document Type: Article

References (67)

1. Stein I., Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29: 181, 1935.
2. McArthur J.W., Ingersoll F.M., Worcester J. The urinary excretion of interstitial cell and follicle-stimulating hormone activity by women with diseases of the reproductive system. J. Clin. Endocrinol. Metab. 18: 1202, 1958.
3. Yen S.S.C., Vela P., Rankin J. Inappropriate secretion of follicle stimulating hormone and luteinizing hormone in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 30: 435, 1970.
4. Anttila L., Ding Y.-Q., Ruutiainen K., Erkkola R., Irjala K., Huhtaniemi I. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease. Fertil. Steril. 55: 1057, 1991.
5. Fauser B.C.J.M., Pache T.D., Lamberty W.J., et al. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J. Clin. Endocrinol. Metab. 73: 811, 1991.
6. Lobo R.A., Kletzky O.A., Campeau J.D., di Zerega G.S. Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. Fertil. Steril. 39: 674, 1983.
7. Rebar R., Judd H.L., Yen S.S.C., Rakoff J., Vandenberg G., Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J. Clin. Invest. 57: 1320, 1976.
8. Conway G.S., Honour J.W., Jacobs H.S. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol. 30: 459, 1989.
9. Franks S. Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol. (Oxf.) 37: 87, 1989.
10. Yen S.S.C. The polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 12: 177, 1980.
11. Zawadzki J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif, A., Givens J.R., Haseltine F.P. Merriam G.R. (Eds.), Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Blackwell Scientific Publications, Boston, 1992, p. 377.
12. Taylor A.E., McCourt B., Anderson E.J., Martin K.A., Adams J.M., Schoenfeld D., Hall J.E. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 82: 2248, 1997.
13. Belchetz E.E., Plant T.M., Nakai Y., Keogh E.J., Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 202: 631, 1978.
14. Conn P.M., Crowley W.F. Jr. Gonadotropin-releasing hormone and its analogues. N. Engl. J. Med. 324: 93, 1991.
15. Spratt D.I., Finkelstein J.S., Butler J.P., Badger T.M., Crowley W.F. Jr. Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men. J. Clin. Endocrinol. Metab. 64: 1179, 1987.
16. Gross K.M., Matsumoto A.M., Bremner W.J. Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man. J. Clin. Endocrinol. Metab. 64: 674, 1987.
17. Finklestein J.S., Badger T.M., O'Dea St.L. Spratt D.I., Crowley W.F. Effects of decreasing the frequency of gonadotropin-releasing hormone stimulation on gonadotropin secretion in gonadotropin-releasing hormone-deficient men and perifused rat pituitary cells. J. Clin. Invest. 81: 1725, 1988.
18. Dalkin A., C., Haisenleder D.J., Ortolano G.A., Ellis T.R., Marshall J.C. The frequency of gonadotropin-releasing hormone stimulation differentially regulates gonadotropin subunit messenger ribonucleic acid expression. Endocrinology. 125: 917, 1989.
19. Papavasiliou S.S., Zmeili S., Khoury S., Landefeld T.D., Chin W.W., Marshall J.C. Gonadotropin releasing hormone differentially regulates expression of the genes for luteinizing hormone alpha and beta subunits in male rats. Proc. Natl. Acad. Sci. 83: 4026, 1986.
20. Kaiser U.B., Sabbagh E., Katzenellenbogen R.A., Conn P.M., Chin W.W. A mechanism for the differential regulation of gonadotropin subunit gene expression by gonadotropin-releasing hormone. Proc. Natl. Acad. Sci. 92: 12280, 1995.
21. Besecke L.M., Guendner M.J., Schneyer A. L., Bauer-Dantoin A.C., Jameson J.L., Weiss J. Gonadotropin-releasing hormone regulated follicle-stimulating hormone-b gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology. 137: 3667, 1996.
22. Gharib S.D., Wierman M.E., Shupnik M.A., Chin W.W. Molecular biology of the pituitary gonadotropins. Endocr. Rev. 11: 177, 1990.
23. Marshall J.C., Case G.D., Val,k T.W., Corley K.P., Sauder S.E., Kelch R.P. Selective inhibition of follicle-stimulating hormone secretion by estradiol. J. Clin. Invest. 71: 248, 1983.
24. Keye W.R. Jr., Jaffe R.B. Strength-duration characteristics of estrogen effect on gonadotropin response to gonadotropin-releasing hormone. I. Effects of varying duration of estradiol administration. J. Clin. Endocrinol. Metab. 41: 1003, 1975.
25. DeKretser D.M., Robertson D.M. The isolation and physiology of inhibin and related proteins. Biol. Reprod. 40: 33, 1989.
26. DePaolo L.V., Bickak T.A., Erickson G.F., Shimasaki S., Ling N. Follistatin and activin: a potential intrinsic regulatory system within diverse tissues. Proc. Soc. Exp. Biol. Med. 198: 500, 1991.
27. Khoury R.H., Wang Q.F., Crowley W.F. Jr, Hall J.E., Schneyer A.L, Toth T., Midgley A.R. Jr, Sluss P.M. Serum Follistatin levels in women: evidence against an endocrine function of ovarian follistatin. J. Clin. Endocrinol. Metab. 80: 1361, 1995.
28. Waldstreicher J., Santoro N.F., Hall J.E., Filicori M., Crowley W.F. Hyperfunction of the hypothalamic-pituitary axis in women with Polycystic Ovarian Disease: Indirect evidence for partial gonadotroph desensitization. J. Clin. Endocrinol. Metab. 66: 165, 1988.
29. Burger C.W., Korsen T., van Kessel H., van Dop P.A., Caron F.J.M., Schoemaker J. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea. J. Clin. Endocrinol. Metab. 61: 1126, 1985.
30. Imse V., Holzapfel G., Hinney B., Kuhn W., Wuttke W. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J. Clin. Endocrinol. Metab. 74: 1053, 1992.
31. Dunaif A., Mandeli J., Fluhr H., Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 66: 131, 1988.
32. Berga S.L., Guzick D.S., Winters S.J. Increased luteinizing hormone and alpha-subunit secretion in women with hyperandrogenic anovulation. J. Clin. Endocrinol. Metab. 77: 895, 1993.
33. Crowley W.F., Taylor A.E., Martin K.A., Whitcomb R.W., Finkelstein J.S., Hall J.E. Use of the free alpha subunit (FAS) of glycoprotein secreting hormones as a surrogate marker of GnRH secretion in the human. In: J.W. Lusbader, J.D. Puett, R. Ruddon (Eds.), Serono Glycoprotein Hormones: Structure, Function and Clinical Implications. Symposia, USA, pp. 253, 1994.
34. Hall J.E., Taylor A.E., Martin K.A., Rivier J., Schoenfeld D., Crowley W.F. Jr. Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women. Proc. Natl. Acad. Sci. U.S.A. 91: 6894, 1994.
35. th Annual Meeting Program and Abstracts 1994, 1525: 582.
36. Hayes F.J., Taylor A.E., Martin K.A., Hall J.E. Use of a GnRH antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroen-docrine and androgen dynamics. J. Clin. Endocrinol. Metab. 83: 2343, 1998.
37. Corenthal L., Von Hagen S., Larkins D., Ibrahim J., Santoro N. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome. Fertil. Steril. 61: 1027, 1994.
38. Christman G.M., Randolph J.F., Kelch R.P., Marshall J.C. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 72: 1278, 1991.
39. Buckler H.M. Phillips S.E., Cameron I.T., Healy D.L, Burger H.G. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 67: 300, 1988.
40. Daniels T.L. Berga S.L. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J. Clin. Endocrinol. Metab. 82: 4179, 1997.
41. Pastor C.L., Griffin-Korf M.L., Aloi J.A., Evans W.S., Marshall J.C. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 83: 582, 1998.
42. Zumoff B., Freeman F., Coupey S., et al. A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N. Engl. J. Med. 309: 1206, 1983.
43. Batrinos M.L. Diagnostic dilemmas in polycystic ovarian syndrome. In: Tolis G., Bringer J., Chrousos G.P. (Eds.) Intra-ovarian Regulators and Polycystic Ovarian Syndrome. Ann. NY Acad. Sci., Philadelphia, 687: 230, 1993.
44. Smith P.F., Frawley L.S., Neill J.D. Detection of LH release from individual pituitary cells by the reverse hemolytic plaque assay: estrogen increases the fraction of gonadotropes responding to GnRH. Endocrinology. 115: 2484, 1984.
45. DeVane G.W., Czekala N.M., Judd H.L., Yen S.S.C. Circulating gonadotropins, estrogens, and androgens in Polycystic Ovarian Disease. Am. J. Obstet. Gynecol. 121: 496, 1975.
46. Lobo R.A., Granger L., Goebelsmann U., Mishell D.B. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO. J. Clin. Endocrinol. Metab. 52: 156, 1981.
47. Chang R.J., Mandel F.P., Liu J.K.H., Judd H.L. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 54: 490, 1982.
48. Dunaif A., Scully R.E., Andersen R.N., et al. The effects of continuous androgen secretion on the hypothalamic-pituitary axis in women: evidence from a luteinized thecoma of the ovary. J. Clin. Endocrinol. Metab. 59: 389, 1984.
49. Finklestein J.S., Whitcomb R.W., O'Dea L.St.L.., et al. Sex steroid control of gonadotropin secretion in the human male. In: Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J. Clin. Endocrinol. Metab. 73: 609, 1991.
50. Serafini P., Silva P.D., Paulson R.J., et al. Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women. Am. J. Obstet. Gynecol. 155: 1288, 1986.
51. Dunaif A. Do androgens directly regulate gonadotropin secretion in the Polycystic Ovary Syndrome? J. Clin. Endocrinol. Metab. 63: 215, 1986.
52. Spinder T., Spijkstra J.J., Gooren L.J.G., Hompes P.G.A., van Kessel H. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. J. Clin. Endocrinol. Metab. 68: 200, 1989.
53. Buckler H.M., McLachlan R.I., MacLachlan V.B., et al. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration. J. Clin. Endocrinol. Metab. 66: 798, 1988.
54. Pigny P., Desailloud R., Cortet-Rudelli C. et al. Serum α-inhibin levels in polycystic ovary syndrome: relationship to the serum androstenedione level. J. Clin. Endocrinol. Metab. 82: 1939, 1997.
55. Lambert-Messerlian G.M., Hall J.E., Sluss P.M., Taylor A.E., Martin K.A,. Groome N.P., Crowley W.F. Jr., Schneyer A.L. Relatively low levels of dimeric inhibin circulate in men and women with PCOS using a specific two-site ELISA. J. Clin. Endocrinol. Metab. 79: 45, 1994.
56. Roberts V.J., Barth S., El-Roeiy A., Yen S.S.C. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J. Clin. Endocrinol. Metab. 77: 1402, 1993.
57. Roberts V.J., Barth S., El-Roeiy A., Yen S.S.C. Expression of inhibin/activin system mRNAs and proteins in ovarian follicles from women with PCOS. J. Clin. Endocrinol. Metab. 79: 1434, 1994.
58. Lockwood G.M., Muttukrishna S., Groome N.P., Matthews D.R., Ledger W.L. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J. Clin. Endocrinol. Metab. 83: 1730, 1998.
59. th International Congress of Endocrinology, San Francisco Program and Abstracts 560: P2-624, 1996.
60. Lambert-Messerlian G., Taylor A., Leykin L. Characterization of intrafollicular steroid hormones, inhibin, and follistatin in women with and without polycystic ovarian syndrome following gonadotropin hyperstimulation. Biol. Reprod. 57: 1211, 1997.
61. Paradisi R., Venturoli S., Pasquali R., Capelli M., Porcu E., Fabbri R., Flamigni C. Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease. J. Endocrinol. Invest. 9: 139, 1986.
62. Kiddy D.S., Sharp P.S., White D.M., Scanlon M.F., Mason H.D., Bray C.S., Poison D.W., Reed M.J., Franks S. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: An analysis of 263 consecutive cases. Clin. Endocrinol. 32: 213, 1990.
63. Morales A.J., Laughlin G.A., Butzow T., Maheshwari H., Baumann G., Yen S.S.C. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J. Clin. Endocrinol. Metab. 81: 2854, 1996.
64. Arroyo A., Laughlin G.A., Morales A.J., Yen S.S.C. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J. Clin. Endocrinol. Metab. 82: 3718, 1997.
65. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18: 774, 1997.
66. Adashi E.Y., Hsueh A.J.W., Yen S.S.C. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 108: 1441, 1981.
67. Flier J.S. What's in a name? In search of leptin's physiologic role. J. Clin. Endocrinol. Metab. 83: 1407, 1998.